June 2025
1. LI H, Pu Z, Fang J
   Effect of Metformin on vascular endothelial injury in patients with non-small cell lung cancer treated with chemotherapy combined with bevacizumab.
   Cancer Chemother Pharmacol. 2025;95:59.
   

   >> Share

   
   March 2025
2. YOKOTA H, Sato K, Sakamoto S, Okuda Y, et al
   Influence of interleukin-6 on the pharmacokinetics and pharmacodynamics of osimertinib in patients with non-small cell lung cancer.
   Cancer Chemother Pharmacol. 2025;95:49.
   

   >> Share

   
   January 2025
3. FUNAISHI K, Yamaguchi K, Tanahashi H, Kurose K, et al
   HMGB1 assists the predictive value of tumor PD-L1 expression for the efficacy of anti-PD-1/PD-L1 antibody in NSCLC.
   Cancer Chemother Pharmacol. 2025;95:28.
   

   >> Share

   
   
4. CHENG CY, Chuang WC, Lin CP, Li CH, et al
   Endoglin as a predictive biomarker for pemetrexed sensitivity in non-small-cell lung cancer: a cellular study.
   Cancer Chemother Pharmacol. 2025;95:20.
   

   >> Share

   
   December 2024
5. GEZELIUS E, Planck M, Hazem B, Nagpal S, et al
   Intrathecal pemetrexed for leptomeningeal metastases in a patient with ALK-rearranged lung adenocarcinoma: a case report.
   Cancer Chemother Pharmacol. 2024;95:6.
   

   >> Share

   
   
6. DE ROUW N, Beunders R, Hartmann O, Schulte J, et al
   A comparison of the renal function biomarkers serum creatinine, pro-enkephalin and cystatin C to predict clearance of pemetrexed.
   Cancer Chemother Pharmacol. 2024;94:799-806.
   

   >> Share

   
   September 2024
7. LIN L, van der Noort V, Steeghs N, Ruiter G, et al
   A joint model of longitudinal pharmacokinetic and time-to-event data to study exposure-response relationships: a proof-of-concept study with alectinib.
   Cancer Chemother Pharmacol. 2024;94:453-459.
   

   >> Share

   
   July 2024
8. YAMAMOTO N, Koyama T, Sato J, Yoshida T, et al
   Phase I study of the anti-TIGIT antibody tiragolumab in combination with atezolizumab in Japanese patients with advanced or metastatic solid tumors.
   Cancer Chemother Pharmacol. 2024;94:109-115.
   

   >> Share

   
   April 2024
9. XU X, Liu Y, Gong Q, Ma L, et al
   PARP1 promotes EGFR-TKI drug-resistance via PI3K/AKT pathway in non-small-cell lung cancer.
   Cancer Chemother Pharmacol. 2024 Apr 12. doi: 10.1007/s00280-024-04668.
   

   >> Share

   
   
10. URYU K, Imamura Y, Shimoyama R, Mase T, et al
    Prognostic impact of concomitant pH-regulating drugs in patients with non-small cell lung cancer receiving epidermal growth factor receptor tyrosine kinase inhibitors: the Tokushukai REAl-world Data project 01-S1.
    Cancer Chemother Pharmacol. 2024 Apr 8. doi: 10.1007/s00280-024-04666.
    

    >> Share

    
    March 2024
11. HUO H, Feng Y, Tang Q
    Correction to: Inhibition of proteinase-activated receptor 2 (PAR2) decreased the malignant progression of lung cancer cells and increased the sensitivity to chemotherapy.
    Cancer Chemother Pharmacol. 2024 Mar 26. doi: 10.1007/s00280-024-04646.
    

    >> Share

    
    February 2024
12. MA X, Sun Z, Chen H, Cao L, et al
    18beta-glycyrrhetinic acid suppresses Lewis lung cancer growth through protecting immune cells from ferroptosis.
    Cancer Chemother Pharmacol. 2024 Feb 21. doi: 10.1007/s00280-024-04639.
    

    >> Share

    
    January 2024
13. YU F, Huo H, Tang Q
    Inhibition of proteinase-activated receptor 2 (PAR2) decreased the malignant progression of lung cancer cells and increased the sensitivity to chemotherapy.
    Cancer Chemother Pharmacol. 2024 Jan 4. doi: 10.1007/s00280-023-04630.
    

    >> Share

    
    
14. LI MY, Zhang J, Lu X, Zhou D, et al
    Ivermectin induces nonprotective autophagy by downregulating PAK1 and apoptosis in lung adenocarcinoma cells.
    Cancer Chemother Pharmacol. 2024;93:41-54.
    

    >> Share

    
    November 2023
15. WANG X, Gu S, Wen J, Zhang L, et al
    Association between chemotherapy-induced myelosuppression and curative efficacy of 2-cycle chemotherapy in small cell lung cancer.
    Cancer Chemother Pharmacol. 2023 Nov 5. doi: 10.1007/s00280-023-04608.
    

    >> Share

    
    
16. MA Y, Chen Q, Zhang Y, Xue J, et al
    Pharmacokinetics, safety, tolerability, and feasibility of apatinib in combination with gefitinib in stage IIIB-IV EGFR-mutated non-squamous NSCLC: a drug-drug interaction study.
    Cancer Chemother Pharmacol. 2023;92:411-418.
    

    >> Share

    
    September 2023
17. CHENG M, Yang F, Yang Y, Gao X, et al
    Correlation analysis between camrelizumab trough concentration levels and efficacy or safety in East Asian patients with advanced lung cancer.
    Cancer Chemother Pharmacol. 2023 Sep 23. doi: 10.1007/s00280-023-04590.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share